Moreover, in clinical trials of nemolizumab, approximately 5% of patients exhibited elevated serum thymus and activation-regulated chemokine (TARC) levels - a Th2-specific chemokine - which were associated with the development of edematous erythema and acute eczema. This evidence concerns the gene CCL17 and Erythema.